New Treatments for Hepatobiliary Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 141
Special Issue Editors
Interests: cancer therapy; metastasis; tumor angiogenesis; angiogenesis; tumors; cancer; cancer diagnostics; hepatocellular carcinoma; cancer immunology; endothelial cells
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hepatobiliary cancers are among the most frequently occurring types of tumor worldwide. After years of unsatisfactory results, combinations of treatments ranging from traditional chemotherapy regimens to immunotherapy have finally changed the approach to advanced disease control, providing better outcomes in the advanced setting, even if locoregional control still remains the primary aim of treatment. This Issue focalizes its attention on new treatments for hepatobiliary cancers in a broader meaning, encompassing issues such the literal proposition of new drugs or treatments; the integration of a current treatment to either locoregional procedures or systemic treatments; and the personalization and optimization of treatments to improve the results of therapies. Therefore, this Issue embraces a wide range of interests: the identification of specific subsets of patients to personalize treatment, the proposal of new locoregional treatments or protocols, the integration of different treatments in any possible setting, the analysis of data from new drugs including immunotherapics, the best indications for already available drugs, the possible improvements in sequences of drugs, and the usefulness of any possible treatment in efforts to enhance responses and tolerance to treatment.
Dr. Girolamo Ranieri
Dr. Davide Quaresmini
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hepatocellular carcinoma
- biliary cell carcinoma
- locoregional treatment
- transarterial chemoembolization
- immunotherapy
- thyrosinkinase inhibitors
- downstaging
- molecular subclasses
- association therapy
- sequencial treatments
